Trastuzumab: updates and future issues (original) (raw)

References

1. Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP (2004) PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res 64:5471–5480
   Article PubMed CAS Google Scholar
2. Barlund M, Kuukasjarvi T, Syrjakoski K, Auvinen A, Kallioniemi A (2004) Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer 111:968–971
   Article PubMed CAS Google Scholar
3. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3656–3659
   Article PubMed Google Scholar
4. Chan-Hui PY, Stephens K, Warnock RA, Singh S (2004) Applications of eTag trademark assay platform to systems biology approaches in molecular oncology and toxicology studies. Clin Immunol 111:162–174
   Article PubMed CAS Google Scholar
5. Citri A, Skaria KB, Yarden Y (2003) The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284:54–65
   Article PubMed CAS Google Scholar
6. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor target. Nat Med 6:443–446
   Article PubMed CAS Google Scholar
7. Finn RS, Slamon DJ (2003) Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif 21:223–233
   PubMed CAS Google Scholar
8. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650–5655
   Article PubMed CAS Google Scholar
9. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE (2001) Overexpression of HER-2 in ovarian carcinomas. Cancer Res 61:2420–2423
   PubMed CAS Google Scholar
10. Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, Czerwenka K (2003) Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 80:353–361
    Article PubMed CAS Google Scholar
11. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356:1795–1799
    Article PubMed CAS Google Scholar
12. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279–280
    Article PubMed CAS Google Scholar
13. Jones RL, Smith IE (2004) Efficacy and safety of trastuzumab. Expert Opin Drug Saf 3:317–327
    Article PubMed Google Scholar
14. Konecny G, Pauletti G, Pergam M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ (2003) Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142–153
    Article PubMed CAS Google Scholar
15. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62:5813–5817
    PubMed CAS Google Scholar
16. Pegram MD, Konecny GE, O’Callaghan C, Beryt M, Pietras R, Slamon DJ (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:725–727
    Article PubMed Google Scholar
17. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O’Brien T, Cannon MJ, Parham GP (2002) Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 8:1271–1279
    PubMed CAS Google Scholar
18. Toi M, Bando H, Chow LW (2004) Novel insights in clinical trial with preoperative systemic therapy for primary breast cancer. Biomed Pharmacother 58:531–535
    Article PubMed Google Scholar
19. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96–102
    PubMed Google Scholar
20. Yokoi A, McCrudden KW, Huang J, Kim ES, Soffer SZ, Frischer JS, Serur A, New T, Yuan J, Mansukhani M, O’Toole K, Yamashiro DJ, Kandel JJ (2003) Blockade of Her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. Oncol Rep 10:1271–1274
    PubMed CAS Google Scholar
21. Zhu L, Chow LW, Loo WT, Guan XY, Toi M (2004) Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 10:4639–4644
    Article PubMed CAS Google Scholar

Download references